Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Farhat Nasim

Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Farhat Nasim

Articles By : Farhat Nasim

La Renon's plea to exempt Sodium Valproate from NPPA price cap rejected

Farhat Nasim31 Oct 2024 2:00 PM IST

New Delhi: The Department of Pharmaceuticals (DoP), functional under India's Ministry of Chemicals and Fertilizers, has rejected an appeal from La...

Cipla Bommasandra facility gets VAI classification from USFDA

DoP orders NPPA to reassess price of Cipla's Advent, Synclar and Azee drugs

Farhat Nasim30 Oct 2024 6:14 PM IST

New Delhi: The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals & Fertilizers, has issued orders to the National...

Severe risk with import of second hand CT scanners, MRI machines, surgical robots, warns industry body, files PIL

Farhat Nasim27 Oct 2024 12:30 PM IST

New Delhi: Medical device manufacturers in India are sounding alarms over the unregulated import of refurbished medical devices, emphasizing serious...

Novartis ianalumab Phase III trial meets primary endpoint in immune thrombocytopenia

Novartis' Ribociclib named as Category 1 Preferred Adjuvant Treatment for Breast Cancer in NCCN Guidelines

Farhat Nasim27 Oct 2024 10:15 AM IST

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib...

Dexcom Beats Quarterly Sales Expectations, Reaffirms Annual Outlook

MD Bureau27 Oct 2024 10:00 AM IST

Analysts had raised concerns about the pace at which Dexcom was capturing "basal only" diabetes patients who take one insulin injection a day

West Pharmas 2025 Forecast Misses Estimates as Inventory Reductions Continue

West Pharma Raises 2024 Profit Forecast Amid Surging Demand for Injectable Therapy Supplies

MD Bureau27 Oct 2024 9:45 AM IST

Bengaluru: West Pharmaceutical Services raised its annual profit outlook on Thursday after exceeding Wall Street's expectations for quarterly...

Delhi HC Orders Arbitration in Medikabazaar Board Dispute, Tiwari Challenges Termination

No violation of Abbott's trademark: Delhi HC upholds trademark of Mebufen against Brufen

Farhat Nasim26 Oct 2024 5:18 PM IST

New Delhi: The Delhi High Court has upheld the Registrar of Trademarks' decision to reject an objection by pharmaceutical giant Abbott, which...

Medtronic gets USFDA nod for OmniaSecure defibrillation lead for placement within right ventricle

Philips, Medtronic Ink Advocacy Partnership to Enhance Stroke Care Access

Farhat Nasim26 Oct 2024 4:27 PM IST

Netherlands: Royal Philips, a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies,...

Biocon appoints Ekta Agarwal as Interim Company Secretary, Compliance Officer

Biocon Foundation Wins 2024 Doing Good for Bharat Award in Healthcare for eLAJ Smart Clinics

MD Bureau26 Oct 2024 2:38 PM IST

Bengaluru: Biocon Foundation, the CSR arm of the Biocon Group of Companies, announced that it has received the esteemed ‘Doing Good for Bharat...

Rhythm Pharma, Axovia Therapeutics Launch Joint Research Collaboration for Bardet-Biedl Syndrome

MD Bureau26 Oct 2024 11:00 AM IST

BOSTON: Rhythm Pharmaceuticals, Inc. and Axovia Therapeutics Ltd. have announced a collaborative research effort aimed at advancing insights into...

Merck, Daiichi Sankyo Ifinatamab deruxtecan granted Breakthrough Therapy Designation by USFDA for pretreated extensive-stage small cell lung cancer

Merck's KEYTRUDA Gains European Approval for Two New Gynecologic Cancer Treatments

MD Bureau25 Oct 2024 5:47 PM IST

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement.

Bayer, Dewpoint ink USD 424 million deal to develop breakthrough therapy for genetic heart disease

MD Bureau25 Oct 2024 3:34 PM IST

Berlin: Bayer has signed an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program targeting patients with...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok